Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1172/JCI80010 http://scihub22266oqcxt.onion/10.1172/JCI80010 C4588281!4588281!26325036     free     free     free       J+Clin+Invest 2015 ; 125 (9): 3392-400 Nephropedia Template TP {{tp|p=26325036|t=2015. CAR therapy: the CD19 paradigm |pdf=|usr=}}{{26325036}} gab.com Text CAR therapy: the CD19 paradigm JO: J Clin Invest http://www.kidney.de/pget.php?&tw=1&pmid=26325036 #FOAvip Twenty-five years after its inception, the genetic engineering of T cells is now a therapeutic modality pursued at an increasing number of medical centers. This immunotherapeutic strategy is predicated on gene transfer technology to instruct T lymphocytes to recognize and reject tumor cells. Chimeric antigen receptors (CARs) are synthetic receptors that mediate antigen recognition, T cell activation, and ? in the case of second-generation CARs ? costimulation to augment T cell functionality and persistence. We demonstrated over a decade ago that human T cells engineered with a CD19-specific CAR eradicated B cell malignancies in mice. Several phase I clinical trials eventually yielded dramatic results in patients with leukemia or lymphoma, especially acute lymphoblastic leukemia (ALL). This review recounts the milestones of CD19 CAR therapy and summarizes lessons learned from the CD19 paradigm. Twit Text FOAVip CAR therapy: the CD19 paradigm ????J Clin Invest http://www.kidney.de/pget.php?&tw=1&pmid=26325036 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26325036 #FOAvip English Wikipedia <ref>{{Cite pmid|26325036}}</ref> CAR therapy: the CD19 paradigm #MMPMID26325036 Sadelain M J Clin Invest 2015[Sep]; 125 (9): 3392-400 PMID26325036show ga Twenty-five years after its inception, the genetic engineering of T cells is now a therapeutic modality pursued at an increasing number of medical centers. This immunotherapeutic strategy is predicated on gene transfer technology to instruct T lymphocytes to recognize and reject tumor cells. Chimeric antigen receptors (CARs) are synthetic receptors that mediate antigen recognition, T cell activation, and ? in the case of second-generation CARs ? costimulation to augment T cell functionality and persistence. We demonstrated over a decade ago that human T cells engineered with a CD19-specific CAR eradicated B cell malignancies in mice. Several phase I clinical trials eventually yielded dramatic results in patients with leukemia or lymphoma, especially acute lymphoblastic leukemia (ALL). This review recounts the milestones of CD19 CAR therapy and summarizes lessons learned from the CD19 paradigm. äCAR therapy: the CD19 paradigm (epmc).pdf DeepDyve Pubget Overpricing